Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (19451)	4/28/1998 7:50:00 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 32384

Only problem with dose based ricing for indications is what a pharmacy normaly stocks and/or as on hand. <I expect the drug to come in different doses with LGND selling the cancer treatment dose, LLY selling the diabetes treatment and prevention dose, and some kind of in between agreement for the cancer prevention dose and cancer combo dose.> For example, if a dose is written for a 200 mg tab BID, and Rx normally stocks only 100s or is out of the 200s, Rx may dispense with two 100's for each dose, with instructions to take two tabs twice daily. In most states, pharmacies also have therapeutic interchange capability. Sometimes they call the doc 1st, sometimes they don't. Less often, in the reverse situation, a higher dose may be broken in two if not availible in the lower dose form. Then there's the problems of sample meds and drug promotions... Hopefuly it will end up as a near wash, but it will not be clear cut. Scott